GeneDx Holdings Corp. Files 8-K on Shareholder Votes and Financials

TL;DR

GeneDx filed an 8-K on June 24th covering shareholder votes and financials as of June 20th.

AI Summary

GeneDx Holdings Corp. filed an 8-K on June 24, 2024, reporting on matters submitted to a vote of security holders and financial statements as of June 20, 2024. The company, formerly known as Sema4 Holdings Corp. and CM Life Sciences, Inc., is incorporated in Delaware and headquartered in Stamford, CT.

Why It Matters

This filing provides updates on corporate actions and financial status, which are crucial for investors to assess the company's performance and governance.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of corporate events and financial statements, not indicating any immediate financial distress or significant operational changes.

Key Players & Entities

• GeneDx Holdings Corp. (company) — Registrant
• Sema4 Holdings Corp. (company) — Former company name
• CM Life Sciences, Inc. (company) — Former company name
• June 24, 2024 (date) — Date of report
• June 20, 2024 (date) — Earliest event date
• Delaware (jurisdiction) — State of incorporation
• Stamford, Connecticut (location) — Business address

FAQ

Key Financial Figures

• $0.0001 — stered Class A common stock, par value $0.0001 per share WGS The Nasdaq Stock Market L
• $379.50 — mon stock, each at an exercise price of $379.50 per share WGSWW The Nasdaq Stock Market

Filing Documents

• wgs-20240620.htm (8-K) — 34KB
• wgs-20240620_g1.jpg (GRAPHIC) — 16KB
• 0001818331-24-000036.txt ( ) — 251KB
• wgs-20240620.xsd (EX-101.SCH) — 2KB
• wgs-20240620_def.xml (EX-101.DEF) — 17KB
• wgs-20240620_lab.xml (EX-101.LAB) — 29KB
• wgs-20240620_pre.xml (EX-101.PRE) — 17KB
• wgs-20240620_htm.xml (XML) — 4KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On June 20, 2024, GeneDx Holdings Corp., a Delaware corporation (the "Company"), held its Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders (the "Stockholders") considered and voted on the matters listed below. The proposals are described in detail in the Company's Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 29, 2024. There were 26,150,866 shares of the Class A common stock issued and outstanding on April 24, 2024, the record date for the Annual Meeting. The Stockholders voted on the following proposals at the Annual Meeting, each of which was approved. The final voting results from the Annual Meeting are set forth below. (1) Proposal No. 1 — The Class III Director Election Proposal —To elect three Class III directors of the Company, each to serve a three-year term expiring at the Company's 2027 annual meeting of stockholders and until such director's successor is duly elected and qualified or until such director's earlier death, resignation, disqualification or removal: Nominee Votes For Votes Withheld Broker Non-Votes Emily Leproust, Ph.D 17,026,055 747,294 5,598,681 Keith Meister 17,230,090 543,259 5,598,681 Richard C. Pfenniger, Jr. 17,201,550 571,799 5,598,681 (2) Proposal No. 2 — The Auditor RatificationProposal — To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024: Votes For Votes Against Abstentions 23,359,773 7,938 4,319

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No Description 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GENEDX HOLDINGS CORP. Date: June 24, 2024 By: /s/ Katherine Stueland Name: Katherine Stueland Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR